Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key Milestone
Details : Hyalofast is a highly differentiated, single-stage, bone preserving, hyaluronic acid matrix, which is intended to support the entrapment of mesenchymal stem cells obtained from autologous bone marrow aspirate concentrate for the repair of chondral and os...
Product Name : Hyalofast
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2023
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Hyaluronate,Triamcinolone Hexacetonide
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anika’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study
Details : Cingal (sodium hyaluronate) combination product of cross-linked hyaluronic acid (HA) proven to provide long lasting pain relief through 6 months plus TH steroid to provide fast, short-term pain relief.
Product Name : Cingal
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2022
Lead Product(s) : Sodium Hyaluronate,Triamcinolone Hexacetonide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable